flow trial semaglutide kidney outcomes hazard ratio 0.76 significant 24% reduction in disease progression and death related to kidney and cardiovascular causes in those treated with compared to a placebo Renal effects of GLP-1 receptor

Weight gain is not always caused by poor eating habits

Several practical factors may explain fatigue during GLP-1 therapy: Reduced food intake due to appetite suppression can lead to lower energy consumption Gastrointestinal side effects like nausea can be physically draining Adaptation to metabolic changes as your body adjusts to the medication For people with diabetes who take insulin or sulfonylureas (like gliclazide) alongside GLP-1 medications, low blood glucose (hypoglycaemia) may cause fatigue

Additionally, many patients experience improvements in related metabolic markers, which is why semaglutide therapy at our Plantation facility addresses not just weight, but overall metabolic health

Endocrinology 18 DrakeN